Small molecule · Inhibitor of FKBP-12 (macrophilin-12) (FKBP1A) and calcineurin (PPP3CA) · developed by Bausch
Pimecrolimus is a calcineurin inhibitor immunosuppressant that binds FKBP-12 and inhibits calcineurin, blocking T-cell activation and the synthesis of several cytokines. It is studied as a topical cream for atopic dermatitis and as an ophthalmic ointment for blepharitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06400511 | Phase 3 | Blepharitis | Terminated | VTRS |
| NCT06052995 | N/A | Mild to Moderate Atopic Dermatitis | Active not recruiting | VTRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mild to Moderate Atopic DermatitisBlepharitis
Updated Nov 1, 2026.